Treg player GentiBio turns to layoffs; Century Therapeutics CEO departs
Treg biotech GentiBio recently enacted layoffs a little more than six months after lining up a pact with Bristol Myers Squibb that could balloon to $1.9 billion.
“Several weeks ago, we implemented a relatively small reduction in force to position us best to respond to the challenging biotech macroenvironment and prolong our runway,” CEO Adel Nada confirmed to Endpoints News in an email. Nada, declining to disclose the size of the reduction, said the layoffs won’t impact operations nor the biotech’s collaborations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.